Stockwinners Market Radar for March 01, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:56 EDT Enstar, Maiden agree to new ADC structure for AmTrust quota share business - Enstar Group Limited (ESGR) announced that it has signed an agreement with Maiden Holdings, Ltd. (MHLD) and Maiden Reinsurance Ltd., a subsidiary of Maiden. Pursuant to the agreement, an Enstar subsidiary will enter into an adverse development cover reinsurance agreement with respect to Maiden Re's quota share reinsurance contracts with AmTrust Financial Services, Inc. (AFSI) and its subsidiaries, for losses incurred on or prior to December 31, 2018 in excess of a $2.44B retention, as such figure may be adjusted based upon Maiden's final year end reserves for the underlying business, up to a $675M limit. The premium payable by Maiden Re will be $500M. Effective immediately upon the signing of the agreement, the parties terminated and released each other from their respective obligations under their previously disclosed agreement related to the Maiden Re quota share agreements with AmTrust, entered into on November 9, 2018. Completion of the transaction is subject to, among other things, regulatory approvals and satisfaction of various closing conditions. The transaction is expected to close in the first half of 2019. Completion of the transaction is subject to, among other things, regulatory approvals and satisfaction of various closing conditions. The transaction is expected to close in the first half of 2019.

17:43 EDT Tonix says FDA rescinds Breakthrough Therapy designation for Tonmya - Tonix Pharmaceuticals Holding Corp. announced program updates related to the development of Tonmya, which is in Phase 3 development for the treatment of posttraumatic stress disorder, or PTSD. The FDA notified the company that the Breakthrough Therapy designation, or BTD, granted for Tonmya for PTSD in December 2016 has been rescinded because interim analysis data on Tonmya from the HONOR study do not support the continuation of the BTD. The BTD granted to Tonmya was based on retrospective analysis of the effect of Tonmya 5.6 mg in the Phase 2 AtEase study in military-related PTSD, that shows a substantial improvement over existing therapies in military-related PTSD. Tonix CEO Seth Lederman commented, "The rescission of Breakthrough Therapy designation of Tonmya for PTSD does not alter our NDA plan and will have minimum impact on our future interactions with the FDA. We are on track to start imminently the Phase 3 RECOVERY trial in civilian and military-related PTSD. We are grateful for the guidance and continued support received from the FDA. We remain committed to expedite the development of Tonmya for PTSD, especially military-related PTSD."

17:39 EDT Tonix Pharmaceuticals trading halted, news pending

17:29 EDT Cardiovascular Systems to replace Nutrisystem in the S&P 600 at open on 3/11 - Cardiovascular Systems (CSII) will replace Nutrisystem (NTRI) prior to the open of trading on Monday, March 11. Tivity Health (TVTY) is acquiring Nutrisystem in a deal expected to close soon pending final conditions.

17:26 EDT Apollo reports 2.4% Class A passive stake, 3.5% Class C passive stake in Clearway Energy - In a regulatory filing, Apollo Management (APO) disclosed that it acquired 2.4% of oustanding class A common shares and 3.5% Class C common shares of Clearway Energy. The filing does not allow for activism.

17:20 EDT Akorn confirms favorable ruling from Delaware Court - Akorn (AKRX) announced that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG (FSNUY) to bring a fraud claim against Akorn. On February 20, Fresenius filed a proposed amended counterclaim seeking to add a new claim for fraud to its existing request for contract damages associated with the termination of the merger agreement with Akorn last year. The Court of Chancery denied Fresenius's motion on February 28, noting that "Fresenius did not previously assert a claim for fraud, and the liability phase of the case has concluded. Fresenius could have asserted a claim for fraud at the outset of the case, or amended its pleadings during discovery or before trial. The parties chose to litigate breach of contract claims. It is too late now to introduce a new theory of liability." Akorn CEO Douglas Boothe said: ""Akorn believes Fresenius's remaining request for contractual damages is without merit, and we will continue to vigorously defend ourselves against it. We are pleased that the Court has ruled in our favor on this motion. This is an important development for us, as we focus on our future and on strengthening the business to enhance shareholder value."

17:04 EDT Oceaneering appoints Witland LeBlanc Jr. Chief Accounting Officer - Oceaneering International announced that Witland LeBlanc Jr., who currently serves as Oceaneering's VP, Tax and Treasury, has been designated to succeed W. Cardon Gerner as VP and Chief Accounting Officer, effective March 15.

16:42 EDT Nektar 'excited' by preliminary data from REVEAL study - Nektar Therapeutics announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262, a novel toll-like receptor 7/8 agonist, in combination with bempegaldesleukin, a CD122-preferential IL-2 pathway agonist. The results were presented today in an oral session at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium by Dr. Adi Diab, Assistant Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. NKTR-262 is designed to induce the body's innate immune response to prime antigen-specific cytotoxic T cells to fight cancer. Bempegaldesleukin is designed to activate the adaptive immune system to expand and proliferate these specific cancer-fighting T cells in the tumor microenvironment. "We're excited by the preliminary data from the REVEAL study which demonstrate desirable changes in the tumor micro-environment consistent with the activation of both the innate and adaptive immune responses induced by NKTR-262 and bempeg," said Dr. Jonathan Zalevsky, Chief Scientific Officer at Nektar. "The early data from REVEAL demonstrate that a comprehensive approach to activating the body's immune system can drive abscopal anti-tumor responses even in the absence of a checkpoint inhibitor. We are looking forward to the ongoing dose-escalation and planned expansion of the study."

16:31 EDT Iconix Brand names John McClain as new CFO - Iconix Brand announced that John T. McClain has been appointed Chief Financial Officer, effective February 11, 2019. Mr. McClain has a strong background in financial leadership positions for global brands. He will report to Robert Galvin, chief executive officer, president and a member of the board of directors at Iconix Brand Group, Inc.

16:22 EDT Chemical Financial, TCF Financial announce leadership appointments for New TCF - Chemical Financial Corporation (CHFC) and TCF Financial Corporation (TCF) announced executive leadership appointments for the combined company. The appointments will become effective upon the closing of the merger of equals, which is anticipated to occur in the late third or early fourth quarter of 2019, subject to satisfaction of customary closing conditions, including receipt of customary regulatory approvals and approval by the shareholders of each company. Each of the individuals named will continue to serve in their current capacity for their respective company until that time. As previously disclosed, Craig Dahl, the current chairman and chief executive officer of TCF, will become chief executive officer and president of new TCF and chief executive officer of the combined bank. David Provost, the current chief executive officer and president of Chemical, will become chairman of new TCF bank. The following executives will report to Dahl: Tom Shafer will become president and chief operating officer of new TCF Bank; Dennis Klaeser will become chief financial officer; Jim Costa will become chief risk & credit officer; Patty Jones will become chief administrative officer; Sandy Kuohn will become chief human capital officer; and Andy Jackson will become chief audit executive. The following executives will report to Shafer: Bill Henak will become executive vice president, wholesale banking; Mike Jones will become executive vice president, consumer and business banking; and Tom Butterfield will become chief information officer.

16:10 EDT Teva launches authorized generic Flector Patch in the U.S. - Teva announced the launch of an authorized generic of Flector Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug, is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with known hypersensitivity to diclofenac or any components of the drug product. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated for use on non-intact or damaged skin resulting from any etiology, including, exudative dermatitis, eczema, infected lesions, burns, or wounds.

16:00 EDT Investment Technology Group trading resumes

15:42 EDT Village Farms trading halted for 'additional information requested' - The Nasdaq Stock Market announced that trading was halted in Village Farms International at 2:23 pm ET for "additional information requested" from the company at a last sale price of $11.888. Trading will remain halted until Village Farms International has fully satisfied Nasdaq's request for additional information.

15:37 EDT Lifeway Foods to enter plant-based beverage category with launch of Plantiful - Lifeway Foods announced it will enter the growing $11B plant-based beverage category with its newest offering, Plantiful. Available in both adult and kids' lines, Plantiful is a vegan beverage that comes in a variety of exciting flavors, each providing more protein and probiotics than other non-dairy beverages in the category. The base is cultured non-GMO pea protein, and the products contain no dairy, gluten or soy and are made with organic ingredients. Shipping this month, Plantiful will be available in 8oz single-serve and 24oz bottles that contain 10 grams of protein and 10 vegan strains of probiotics, providing both functional nutrition and microbiome support. The kid-friendly Plantiful pouches coming this spring are a complementary follow-up to the successful ProBugs line of kefir products that have introduced new generations of Lifeway fans to the brand. Plantiful Kids comes in a convenient, squeezable pouch with a no-spill spout and features the same substantial nutrition and probiotics as the adult line. Both lines will be available nationwide at select natural grocery and retail stores.

15:18 EDT Block says price cuts, delivery times point to demand issues at Tesla - Carson Block of Muddy Waters, who has previously disclosed that he holds a short position in Tesla, is being interviewed on CNBC.

15:12 EDT Peoples Bancorp receives regulatory clearance for First Prestonsburg merger - Peoples Bancorp announced that it has received all necessary regulatory approvals for the merger between Peoples and First Prestonsburg Bancshares Inc. and for the merger between Peoples Bank and First Prestonsburg's wholly owned subsidiary, First Commonwealth Bank of Prestonsburg, Inc. On February 12, 2019, the shareholders of First Prestonsburg approved the merger with Peoples through adoption of the previously announced definitive merger agreement, pursuant to which First Prestonsburg will merge with and into Peoples, and First Commonwealth will subsequently merge with and into Peoples Bank. Peoples expects that the closing of the merger with ASB will occur early in the second quarter of 2019. Completion of the merger remains subject to the satisfaction of customary closing conditions set forth in the merger agreement.

14:30 EDT Bsquare enters into global partner agreement with Microsoft - Bsquare Corporation (BSQR) announced today that it has entered into a Global Partner Agreement with Microsoft (MSFT), effective March 1, 2019. The GPA, which has no fixed expiration date, allows Bsquare to sell Microsoft Windows Embedded operating systems throughout the Americas and replaces Bsquare's previous Microsoft OEM Distribution Agreement with respect to those territories, which expired on February 28, 2019. Microsoft also extended Bsquare's existing ODA covering the European Union, the European Free Trade Association, Turkey, and Africa through June 30, 2019, at which point it will expire and not be renewed. In 2018, Bsquare obtained 3.7% of third-party software sales from the EMEA ODA, or 3.0% of total 2018 revenue. The mid-year expiration of this agreement means that the company will reduce its planned sales and marketing investment in the EMEA related to this line of business.

13:30 EDT TLS reports 9% stake in Ovid Therapeutics, in talks with management - Mark Feldberg's TLS Advisors disclosed a 9.0% stake in Ovid Therapeutics, which represents over 3.34M shares. The filing with the SEC allows for activism. Feldberg has spoken to Dr. Jeremy Levin and various board Members, and expects to continue to speak with the management of the company to discuss "enhancing shareholder value, improving asset optimization, and understanding market response to the activities" of the company, TLS said in a regulatory filing. Feldberg is open to taking a more active role with Ovid "should the situation present itself," the firm added. Ovid Therapeutics in afternoon trading is down 1c to $2.05.

13:14 EDT Microsoft announces new 365 security and workplace features - In a blog post, Microsoft announced a new set of features that are available on Microsoft 365. New security features include the ability to extend a user's security team's capability with Microsoft Threat Experts, allowing healthcare professionals to securely communicate and collaborate, creating better movement between modern desktop and cloud with Desktop App Assure and FastTrack, and the ability to receive Microsoft account security alerts on mobile. In terms of task management and data capture, new features include the ability to add data to Excel directly from a photo of a dataset and the ability to add photos and files to tasks in Microsoft To-Do. Reference Link

12:43 EDT Kroger, Sprouts Farmers Market slide after report of Amazon grocery store plans - Kroger (KR) shares are down 4.5% and Sprouts (SFM) has declined 1% following the WSJ report that Amazon plans to open grocery stores.

12:30 EDT Willdan Group to acquire The Weidt Group, terms not disclosed - Willdan Group, Inc. announced that it has signed a letter of intent with EYP to acquire substantially all of the assets of its energy practice division, The Weidt Group. The Weidt Group is an energy consulting and software development firm that specializes in the energy and operational performance of new and existing buildings for utilities. The Weidt Group achieved approximately $14M of revenue in 2018, and Willdan expects the acquisition to be accretive to earnings in 2019. The acquisition is expected to close in March 2019 and is subject to the execution of an Asset Purchase Agreement and contract novations.

12:05 EDT Bayer's sorafenib granted FDA orphan designation - Bayer HealthCare Pharmaceuticals' sorafenib was granted FDA orphan designation as a treatment of desmoid tumors/aggressive fibromatosis, according to a post to the agency's website. Reference Link

12:00 EDT Maxar Technologies falls -19.4% - Maxar Technologies is down -19.4%, or -$1.42 to $5.89.

12:00 EDT Gap rises 18.9% - Gap is up 18.9%, or $4.79 to $30.20.

12:00 EDT Castlight Health rises 22.1% - Castlight Health is up 22.1%, or 70c to $3.89.

11:51 EDT Alamos Gold trading resumes

11:45 EDT Lyft announces driver bonuses, directed share program opportunity - Lyft announced that, in connection with its milestone year, which it expects to include its initial public offering, Lyft will be paying the most dedicated drivers on its platform bonuses as recognition for their contributions to its success. Lyft will pay a cash bonus of: $1,000 to drivers in good standing who have completed at least 10,000 rides but fewer than 20,000 rides on its platform as of February 25, 2019; $10,000 to drivers in good standing who have completed at least 20,000 rides on its platform as of February 25, 2019; or $1,000 to drivers in good standing who are serving on, or who have served on, its Driver Advisory Council as of February 25, 2019. As part of this program, drivers will receive only one bonus, which will be the largest bonus for which they are eligible. These bonuses are expected to be paid to eligible drivers on or about March 19, 2019. In addition, Lyft announced that these same drivers shall be given the opportunity to use their bonuses to purchase shares of Lyft's Class A common stock in its proposed initial public offering at the initial public offering price through a directed share program. While these drivers may choose to use their bonus to purchase shares through the directed share program, they are under no obligation to do so.

11:35 EDT Alamos Gold receives operating permit for Kirazh project - Alamos Gold reported it has been granted the Operating Permit from the Turkish Department of Energy and Natural Resources allowing for the start of earthworks on the open pit area of the Kirazh project. As disclosed in January 2019, the company expects to spend $75M in 2019 on completing work on the water reservoir and ramping up major construction activities and earthworks. The remaining $60M of Kirazh's total initial capital budget of $152M will be spent in 2020 with initial production expected by the end of 2020. As outlined in the 2017 feasibility study, Kirazh has a 44% after-tax internal rate of return and is expected to produce over 100,000 ounces of gold during its first full year of production at mine-site all-in sustaining costs of less than $400 per ounce. This is expected to bring consolidated production to over 600,000 ounces per year, while significantly lowering the company's cost profile.

11:09 EDT Nissan reports February U.S. sales down 12% to 114,342 units - Nissan Group announced total U.S. sales for February of 114,342 units, a decrease of 12% compared to the prior year. Nissan Division sales totaled 103,735 units, down 11.4% from last February, while Infiniti sales were 10,607 units, down 17.3% year-over-year.

10:37 EDT Versum Materials trading resumes

10:27 EDT Marriott sees 'no material impact' to RevPAR from legacy SPG system data breach - Comments provided during Q4 earnings conference call.

10:24 EDT Versum Materials board rejects unsolicited proposal from Merck KGaA

10:20 EDT Fiat Chrysler reports February U.S. sales down 2% to 162,036 vehicles - FCA US reported that the Jeep Cherokee set an all-time February sales record, despite another month of bitter weather across key selling regions for the brand. The Ram brand scored another record month as well, on the back of award-winning products in the hot light-duty and heavy-duty markets. Following 11 straight months of year-over-year sales increases, the company's overall U.S. February sales retreated 2 percent to 162,036 vehicles in a soft market, compared with sales of 165,903 vehicles in February 2018. The Jeep brand is returning to a more "normal" sales cadence after benefiting from both the new and old Wrangler coming off the production lines this time last year. "The overall industry is starting off slower due in part to weather, the U.S. government shutdown, and concern over tax refunds," U.S. Head of Sales Reid Bigland said. "We still see a strong, stable economy and anticipate any lost winter sales will be made up in the spring. For us, the Ram brand was the standout in February, and Jeep Cherokee set a February record as well."

10:05 EDT Exxon Mobil to fund polypropylene production unit in Baton Rouge - ExxonMobil said that it will fund the construction of a new polypropylene production unit in Baton Rouge that will expand production capacity along the Gulf Coast by up to 450,000 tons per year. Construction will begin in 2019 and startup is anticipated by 2021. The project is expected to create up to 600 jobs during construction and 65 permanent jobs once completed. The engineering, procurement and construction contract has been awarded to Baton Rouge-based Turner Industries and Jacobs Engineering. The companies will use local workers to design and construct the new facility. This new project is in addition to ExxonMobil's previously announced plans to invest $20B to build and expand manufacturing facilities in the U.S. Gulf region as part of its Growing the Gulf initiative, which is expected to create more than 45,000 high-paying jobs across the region.

10:00 EDT 3D Systems falls -9.8% - 3D Systems is down -9.8%, or -$1.38 to $12.74.

10:00 EDT Maxar Technologies falls -23.6% - Maxar Technologies is down -23.6%, or -$1.73 to $5.58.

10:00 EDT Gap rises 18.7% - Gap is up 18.7%, or $4.75 to $30.14.

09:47 EDT 58.com falls -7.2% - 58.com is down -7.2%, or -$5.24 to $67.67.

09:47 EDT Maxar Technologies falls -25.3% - Maxar Technologies is down -25.3%, or -$1.85 to $5.46.

09:47 EDT Farfetch rises 19.2% - Farfetch is up 19.2%, or $4.70 to $29.20.

09:33 EDT Comcast names Thomas Reid general counsel, secretary - Comcast Corporation announced it has named Thomas Reid senior executive vice president, general counsel, and secretary of the company, reporting to CEO Brian Roberts. Reid will join Comcast in April from Davis Polk & Wardwell, where he has served as chairman and managing partner of the firm since 2011. He will be based at Comcast's headquarters in Philadelphia. For nearly four years, he has served as Davis Polk's lead partner with Comcast, and has played a critical role in recent significant transactions, including the Sky acquisition completed last year.

09:29 EDT Connection awarded USNH contract - Connection announced that Connection Public Sector Solutions has been awarded the USNH Joint Computer Purchase Program contract by the University System of New Hampshire, or USNH. Connection will now serve as the provider of computer hardware products and services to all USNH institutions, including the University of New Hampshire, Plymouth State University, Keene State College, and Granite State College, for an initial contract period of three years, with two additional one-year extensions. The Joint Computer Purchase Program provides affordable desktops, laptops, accessories, and services to 34,000 students, parents, faculty, staff, alumni, and institutional departments. USNH also partners with community colleges throughout New Hampshire, providing them with opportunities to take advantage of pricing, terms, and incentives available through the program.

09:16 EDT Autoliv nominates board directors, announces agreement with Cevian - Autoliv announced its nominees for election by the stockholders to the Board of Directors at the 2019 Annual Stockholders Meeting and an agreement with Cevian Capital II GP Limited. All currently serving directors are nominated for re-election at the 2019 Annual General Meeting. Pursuant to the agreement with Cevian, Autoliv agreed to take action to nominate Min Liu for election at the 2019 AGM and nominate her or another designee of Cevian at future annual meetings of Autoliv, subject to the terms and conditions of the agreement, including Cevian maintaining at least 8% ownership position in the common stock of Autoliv. Cevian has agreed to certain customary standstill and voting provisions, including not acquiring more than 19.9% of the common stock of Autoliv. Liu is a Vice President of Cevian Capital AG, an affiliate of Cevian, Autoliv's largest stockholder. Autoliv's Board also approved an increase in the size of the Board from nine to ten members effective as of the open of the polls at the 2019 Annual Meeting in conjunction with its decision to nominate Ms. Liu for election by the stockholders at the 2019 Annual Meeting.

09:14 EDT Cimarex Energy announces closing of Resolute Energy acquisition - Cimarex Energy (XEC) announced that it completed its acquisition of Resolute Energy Corporation (REN) on March 1, 2019. Resolute stockholders were able to elect to receive all cash, all stock or a combination of the two, subject to proration, so that the aggregate merger consideration consisted of no more than 60 percent shares of Cimarex Common Stock and 40 percent cash, based on the closing sale price for shares of Cimarex Common Stock on November 16, 2018. Following proration, Cimarex issued approximately 5.7M shares of Cimarex Common Stock and paid $325.6M in cash to former holders of Resolute Common Stock and Resolute Equity Awards. At closing the total amount of funds necessary to pay the cash portion of the merger consideration, pay transaction fees and expenses and repay in full the amount outstanding under Resolute's revolving credit facility was approximately $615M, which Cimarex funded with cash on hand. In connection with the merger and concurrently with the closing, Cimarex also deposited funds sufficient to redeem any $600M 8.50% Senior Notes of Resolute outstanding on April 1, 2019, using cash on hand and borrowings under Cimarex's revolving credit facility, satisfying and discharging the indenture governing the 8.50% Senior Notes. As of March 1, 2019, we had $525M in borrowings outstanding under our revolving credit facility, leaving an unused borrowing availability of $722.5M. CEO Tom Jorden stated, "We are ready to get to work on the high-quality assets we acquired from Resolute and are commencing completion operations on wells on the acquired acreage in the next few days." He went on to say, "Cimarex is committed to cash flow neutrality in 2019, including payment of our common stock dividend. We can achieve this at a $52.50 NYMEX oil price and grow oil production." In recently provided 2019 production guidance, Cimarex assumed a contribution from the Resolute assets for the month of March of 28,000 barrels of oil equivalent per day. This estimate takes into account volumes that are expected to be shut in to accommodate nearby completion operations. Cimarex estimates combined year over year production growth of 18 percent at the midpoint of guidance, with oil expected to grow 23 percent at the midpoint.

09:11 EDT DHI Group appoints Mitek CEO Scipio Carnecchia to board - DHI Group (DHX) announced Scipio "Max" Carnecchia and David Windley have been appointed to the Company's board of directors. John Barter, current Chairman of the Board, and Burton Goldfield, member of the audit committee, have decided not to stand for re-election at the Company's 2019 annual meeting in May, however Mr. Barter and Mr. Goldfield will serve out the remainder of their terms until the annual meeting. The Company also announced Brian "Skip" Schipper will become the Chairman of the Board at the Company's annual meeting after Mr. Barter completes his term. Carnecchia has more than 20 years of experience leading enterprise software, SaaS and analytics firms. He currently serves as the CEO and member of the board at Mitek Systems (MITK). Windley has more than 30 years of human resources experience globally in industries ranging from construction/engineering, insurance, entertainment/software and technology. The former Chief Human Resources Officer at Yahoo! and Fusion-io, he currently serves as CEO of IQTalent Partners, a professional services firm focused on talent acquisition. With these two new additions, the board of directors for DHI Group will expand to ten members, nine of whom are independent, for a transition period until the Company's annual meeting in May, when Mr. Barter and Mr. Goldfield's terms expire. After that, the board of directors will return to eight members, seven of whom are independent.

09:08 EDT Takeda granted orphan status for multiple myeloma treatment - The FDA granted Takeda Pharmaceutical orphan status for its treatment of multiple myeloma. Reference Link

09:07 EDT BlueMountain nominates 13 director candidates to PG&E board - Blue Mountain Credit Alternatives Master Fund announced that it has nominated a new slate of 13 candidates for election to the Board of Directors of PG&E Corporation at the Company's Annual Meeting scheduled to be held on May 21, 2019. BlueMountain issued an open letter to PG&E shareholders introducing its nominees, which read in part: "Since BlueMountain's update on February 13, 2019, we have engaged in collaborative, good faith discussions with the Company in an attempt to reach an agreement on the composition of a Board that we believe has the experience, knowledge, and ability to turn around PG&E and build a sound future for the Company and the people of California. While we hope to continue these constructive discussions and are open to considering incumbent board members, this morning we submitted our formal notice of nomination. We believe it is important that all shareholders and all Californians understand the high caliber of the candidates willing to serve on the Board and work diligently to address the challenges facing PG&E...We believe the Company must work collaboratively with the public sector, and make safety, risk management, governance, accountability, and transparency its top priorities. The New Slate would bring directors with the experience to address these priorities. Phil Angelides served as Chairman of the U.S. Financial Crisis Inquiry Commission, which conducted the nation's official investigation into the 2008 financial meltdown...Kenneth Feinberg is well-known and highly regarded for his fair and efficient leadership in resolving victims' claims. Mr. Feinberg was appointed by the U.S. government to oversee the September 11th Victim Compensation Fund, jointly by the U.S. government and BP to oversee the Deepwater Horizon oil spill fund, by the Commonwealth of Massachusetts to oversee the fund to provide assistance to the victims of the Marathon bombing, and by Volkswagen as a consultant to the fund to compensate owners of vehicles with diesel emissions in excess of the legal limit...Christopher Hart is a former Chairman of the National Transportation Safety Board and has decades of experience in safety administration and oversight of complex hazardous industries, including the gas pipeline explosion in San Bruno in 2010...Fred Buckman served as the CEO of Consumers Energy, which serves nearly 3.5 million customers in Michigan with about 6.5 gigawatts of electricity and over 300 Bcf of annual natural gas deliveries...Donald Chappel served as CFO of The Williams Companies for more than 14 years...David Crane served as the CEO of NRG Energy, which serves nearly 3 million customers and operates 23 gigawatts of generation across the U.S...Tanuja Dehne served as NRG Energy's CAO where she oversaw the Human Resources, Information Technology, Communications, Corporate Marketing, and Sustainability departments... Dick Rosenblum served as the CEO of Hawaiian Electric Company, which serves nearly 95% of the population of Hawaii over five separate islands and manages over 1 gigawatt of generation...Alvaro Aguirre was a managing director at Warburg Pincus, an investment banker at Morgan Stanley, and a securities lawyer at Sullivan & Cromwell...Marjorie Bowen was an investment banker for 19 years at Houlihan Lokey where she was a member of the firm's senior management, advised corporate boards on strategic transactions, and headed the fairness opinion practice...Mark Lerdal has more than 30 years of experience as an investor, board member, operating executive, and attorney in renewable energy. He currently serves as the Executive Chairman at Leaf Clean Energy, a renewable and sustainable technology investment firm...Barbara Lloyd has 30 years of experience in government, public finance, and project finance. She was a Managing Director in the Infrastructure Advisory Group at KPMG and she worked as a Public Finance banker at Lehman Brothers...Jeffrey Ubben is a founder and the Chief Executive Officer of ValueAct Capital, a San Francisco, California-based investment firm...We strongly believe the New Slate represents the best path forward for the Company. We encourage our fellow shareholders to vote for the New Slate in connection with the Company's Annual Meeting on May 21, 2019."

09:05 EDT Disney announces extension of exchange offers, consent solicitations for 21CFA - Disney (DIS) announces the extension of the expiration date of the offers to exchange any and all outstanding notes issued by 21st Century Fox America, or 21CFA, (FOX, FOXA) for up to $18,128,740,000 aggregate principal amount of new notes to be issued by TWDC Holdco 613 Corp. and cash and the related consent solicitations being made by New Disney on behalf of 21CFA to adopt certain proposed amendments to the indentures governing the 21CFA Notes. New Disney hereby extends such expiration date from 5:00 p.m., New York City time, on March 5, 2019, to 5:00 p.m., New York City time, on March 12.

08:59 EDT Resolute Energy trading halted, news dissemination

08:53 EDT Merck, AstraZeneca receive positive EU CHMP opinion for LYNPARZA - AstraZeneca (AZN) and Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion, recommending the use of LYNPARZA tablets, as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor HR-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

08:48 EDT Eaton intends to spin off lighting business - Eaton announced that it intends to pursue a tax-free spin-off of its Lighting business. The spin-off will create an independent, publicly traded company and is expected to be completed by the end of 2019. Goldman Sachs is serving as Eaton's financial advisor on the transaction. The Lighting business is one of the world's leading providers of LED lighting and control solutions. Its broad range of innovative products and systems are designed to maximize performance and energy efficiency. The business, which had sales of $1.7 billion in 2018, serves customers in commercial, industrial, residential and municipal markets. This potential transaction will be discussed today during the company's annual investor conference. Following the event, access to the conference materials will be available to all interested parties via a link on the center of Eaton's home page. An audio replay of the webcast will be available at the same link.

08:44 EDT Pfizer receives positive opinion for LORVIQUA from CHMP - Pfizer announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a positive opinion for LORVIQUA, an anaplastic lymphoma kinase, or ALK, tyrosine kinase inhibitor, or TKI. The CHMP has adopted a positive opinion recommending conditional marketing authorization for LORVIQUA as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy, or crizotinib and at least one other ALK TKI. Conversion to normal approval will be contingent on provisions of comprehensive data confirming that the benefit-risk balance is positive. The CHMP's opinion will now be reviewed by the European Commission, with a decision expected in the coming months.

08:35 EDT NEEKA Healthcare Canada, Canopy Growth to unveil research initiative - "We would like to invite you to join us as NEEKA Healthcare Canada and Canopy Growth unveil a transformative clinical research initiative in partnership with the NHL Alumni Association, a passionate advocate for improving the health and quality of life for all former NHL players." There will be a press conference featuring Glenn Healy, Executive Director with the NHLAA and former NHL player, Dr. Amin Kassam from NEEKA Healthcare Canada, and from Canopy Growth, Dr. Mark Ware, Chief Medical Officer and Hilary Black, Chief Advocacy Officer. Additional former NHL players will also be in attendance, said the notice.

08:29 EDT Sanofi announces positive CHMP opinion for Dupixent, recommends approval in EU - The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for Dupixent, recommending its approval in the European Union, or EU, for use in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised FeNO who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment. The positive CHMP opinion is based on clinical data from 2,888 adults and adolescents who participated in three pivotal trials from the global LIBERTY ASTHMA program, including the Phase 3 QUEST and VENTURE trials. QUEST compared Dupixent vs. placebo in asthma patients inadequately controlled on a medium or high dose inhaled corticosteroid and a second controller medication. VENTURE compared Dupixent vs. placebo in oral corticosteroid dependent asthma patients. The European Commission is expected to make a final decision on the application for Dupixent in the coming months.

08:21 EDT Intrexon reports expectation for 'going concern' warning in upcoming 10-K - Intrexon stated along with its earnings report last night: "Based on Intrexon's financial position, including its cash, cash equivalents and short-term investments of $224 million at December 31, 2018, in connection with issuing its financial statements Intrexon expects to include a conclusion in its Form 10-K that there is substantial doubt about its ability to continue as a going concern." Chairman and CEO Randal Kirk said, "With several of the most ambitious stated objectives at the time of our IPO now achieved, most notably with our work in UltraCAR-T and in natural gas upgrading, our team is more energized than ever to establish its tangible value in the world. We expect to achieve this initially through independent equitization and/or monetization events at Precigen and from our Methane Bioconversion Platform, while other business units of our company may also find higher values independently of our company. It has always been our purpose to be an enabler of enterprise that is built on engineered biology and not to create an industrial conglomerate. In this we have succeeded greatly so we look forward to seeing some of our bold enterprises making their marks in the world. We are confident in our prospects to achieve this and that we have adequate cash resources to fuel us to these realizations."

08:20 EDT comScore announces CNN to use cross-platform video advertising solution - Comscore announced that CNN is the first media brand to move beyond the Comscore Campaign Ratings beta program, and will now add the cross-platform video advertising solution to its measurement capabilities available to marketers. In September of last year, Comscore launched the CCR beta program in partnership with ten other leading media brands. Since the launch of the program, several other major networks also joined the beta to begin testing the solution, which provides media buyers and sellers with unduplicated measurement of video ad campaigns across linear TV, over-the-topc, desktop and mobile platforms

08:18 EDT eBay enters into cooperation agreements with Elliott, Starboard affiliates - eBay has entered into a cooperation agreement with affiliates of Elliott, who hold more than a 4% economic interest in eBay. eBay has also entered into a cooperation agreement with affiliates of Starboard Value, who hold an economic interest of approximately 1% in eBay. Under the terms of their respective agreements, each of Elliott and Starboard have agreed to certain standstill, voting, and other provisions with eBay. The cooperation agreements will be filed on a Form 8-K with the Securities and Exchange Commission.

08:16 EDT eBay initiates strategic review of asset portfolio - eBay, with the assistance of external financial advisors, has initiated a strategic review of its asset portfolio, including but not limited to StubHub and eBay Classifieds Group. There can be no assurance that the strategic review being undertaken will result in a sale, spin-off or other business combination involving eBay's assets. eBay does not intend on making further public announcements regarding the strategic review unless and until the Board has approved a course of action requiring disclosure.

08:15 EDT eBay announces strategic initiatives to enhance performance - eBay announced several new initiatives with the goal of positioning eBay for ongoing success and value creation. These initiatives include an operating review and the commencement of a strategic review of the Company's portfolio of assets, including StubHub and eBay Classifieds Group. eBay has worked collaboratively with Elliott Management, Starboard Value, and other significant shareholders on these initiatives, which include the addition of two new independent directors to the Board. In a process initiated by eBay's Board of Directors and management late in 2018, these initiatives build on the capital allocation measures announced by eBay in January, including the introduction of a quarterly dividend and the return of $7 billion of capital to shareholders over the next two years. Additionally, eBay is highly focused on driving meaningful operational improvement. This is demonstrated by recently announced significant restructuring measures, including streamlining operations by consolidating the Company's Marketplaces regions under a single global leadership team while also funding significant incremental investments in payments and advertising initiatives.

08:13 EDT Sanofi, Lexicon announce positive CHMP opinion on Zynguista MAA - The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion on the marketing authorization, or MAA, of Zynquista, developed by Sanofi (SNY) and Lexicon (LXRX).The CHMP recommended approval of sotagliflozin in the European Union in both a 200-mg and 400-mg dose for use as an adjunct to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus with a body mass index of 27 kg/m2, who have failed to achieve adequate glycemic control despite optimal insulin therapy. Sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-dependent glucose co-transporter types 1 and 2.1 SGLT1 is responsible for glucose absorption in the gastrointestinal tract,2 and SGLT2 is responsible for glucose reabsorption by the kidney.

08:09 EDT Outlook Therapeutics submits ONS-5010 IND to FDA - Outlook Therapeutics announced the submission of its investigational new drug, or IND, application with the FDA for ONS-5010. ONS-5010 is a monoclonal antibody, or mAb, therapeutic product candidate being developed for wet age related macular degeneration, or wet AMD, diabetic macular edema and branch retinal vein occlusion. Once effective, the IND will allow the company to begin enrolling patients in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial in patients with wet AMD.

08:06 EDT Masco to explore strategic alternatives for Cabinetry and Window businesses - Masco announced that it will explore strategic alternatives for its Cabinetry and Window businesses. "Over the past five years, we have been executing our strategy to drive the full potential of our core businesses, leverage opportunities across our organization, and actively manage our portfolio to drive shareholder value," said Keith Allman, Masco's President and CEO. "Our Cabinetry and Window businesses are leaders in their respective markets and are well positioned to continue their growth. However, we believe we can potentially drive greater shareholder value by exploring strategic alternatives for these businesses. We expect to complete this review by the end of June." For 2018, the Cabinetry Products and Windows and Other Specialty Products segments on a combined basis reported $1.7 billion in net sales, $120 million in operating profit and $161 million in adjusted EBITDA (defined as operating profit plus depreciation and amortization expense of $36 million and excluding $5 million of rationalization charges), which represented 20 percent of Masco's consolidated net sales, 10 percent of consolidated operating profit, and 11 percent of consolidated adjusted EBITDA.

07:59 EDT Concert Pharmaceuticals reports interim CTP-543 Phase 2 data in alopecia areata - Concert Pharmaceuticals announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the American Academy of Dermatology Annual Meeting on March 2, 2019, in Washington, DC. The interim results from this dose-ranging trial showed that treatment with CTP-543 administered at an 8 mg twice-daily dose for 24 weeks met the primary endpoint with a statistically significant greater hair regrowth responder rate compared to placebo. The primary endpoint measures the proportion of patients who are responders to treatment, defined as a greater than or equal to 50% relative reduction in their overall Severity of Alopecia Tool score from baseline. The responders in the 8 mg twice-daily dose group were evenly distributed among patients with patchy alopecia areata and the more severe forms, alopecia totalis and alopecia universalis. The percentage of patients achieving the primary endpoint continued to increase up to Week 24, and regrowth of hair did not appear to plateau at Week 24. For the 4 mg cohort, 21% of patients achieved a greater than or equal to 50% relative reduction in their overall SALT score from baseline, however these differences were not significantly different from placebo. The most common side effects in the interim analysis were headache, upper respiratory tract infection, cough, acne and nausea. No serious adverse events were reported.

07:46 EDT TG Therapeutics presents final data from Phase 2 ublituximab trial at ACTRIMS - TG Therapeutics announced the final results from the Phase 2 multicenter trial of ublituximab, the company's novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis, or RMS. The data were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS. An annualized relapse rate of 0.07 was observed with 93% of subjects relapse free at Week 48. Median B cell depletion was greater than 99% at the primary analysis point of Week 4 and maintained at Week 24 and Week 48. Ublituximab completely eliminated all of T1 Gd-enhancing lesions at Week 24 and maintained complete elimination at Week 48 with 10.6% reduction in T2 lesion volume from baseline to Week 48. Ublituximab was well tolerated across all patients including those receiving rapid infusions, as low as a one hour for the 450mg dose currently being studied in the Phase 3 ULTIMATE program and no study drug related discontinuations occurred. These data support the ongoing, fully enrolled, international Phase 3 program evaluating ublituximab for the treatment of RMS. The Phase 3 trials, entitled ULTIMATE I and ULTIMATE II, are being conducted under special protocol assessment, or SPA, agreement with the FDA.

07:41 EDT Endo to present late-breaking Phase 3 CCH data at AAD - Endo International announced that it will present new data showing collagenase clostridium histolyticum significantly met the clinical endpoint of improved cellulite severity and appearance and was well tolerated in recent Phase 3 clinical trials. The Phase 3 data will be presented on March 2, 2019 during the 'Late-breaking Research: Procedural Dermatology' session at the 2019 Annual Meeting of the American Academy of Dermatology taking place in Washington, DC. The RELEASE-1 and RELEASE-2 Phase 3 studies, which were identically designed, randomized, double blinded and placebo-controlled, assessed the efficacy, safety and tolerability of CCH for the treatment of cellulite in women. A greater percentage of the 843 women treated during the studies met the primary endpoint of response with CCH versus placebo in both the RELEASE-1 and RELEASE-2 studies. In addition, statistically significant improvements with CCH versus placebo were observed for 8 of 8 and 7 of 8 secondary endpoints. Other patient-centric endpoints were also evaluated, including improvement in the Subject Global Aesthetic Improvement Scale, a 5-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the subject. Most adverse events observed in CCH-treated patients were mild/moderate and injection-site related.Additionally, an encore e-poster presentation of the Human Pharmacokinetics of Subcutaneous CCH and Preclinical Safety of Inadvertent Intravenous Administration will be available for viewing at the AAD Annual Meeting.

07:38 EDT E.W. Scripps sees local media revenue up mid-single digits in Q1 - Sees retransmission revenue up high teens. Sees Local Media expense up mid-single digits. Sees National Media revenue In the low-to-mid $80M range. Sees National Media expense about $80M. Sees Shared services and Corporate about $14M. Sees Interest expense about $9M. Sees Pension expense about $2M. Sees Capex in the high-single-digit millions. Sees Depreciation & amortization about $18M.

07:32 EDT BioMarin receives positive CHMP opinion for Palynziq - BioMarin Pharmaceutical announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion for the company's Marketing Authorization Application for Palynziq Injection to reduce blood phenylalanine concentrations in patients with phenylketonuria aged 16 and older, who have inadequate blood Phe control despite prior management with available treatment options. In addition, the CHMP noted that the data collected in the Phase 3 trial and extension study was suggestive of an improvement in inattention and mood symptoms. In May 2018, Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, received regulatory approval from the U.S. Food and Drug Administration, making it the first approved enzyme substitution therapy to target the underlying cause of PKU by helping the body break down Phe. The EC, which typically adheres to the recommendation of the CHMP, is expected to make its final decision on Palynziq in Q2 2019. The CHMP based its opinion on the totality of data from the Palynziq clinical development program including a Phase 3 pivotal study, PRISM-2, which showed that a group of patients taking either 20 mg or 40 mg of Palynziq maintained mean blood Phe levels at 553.0 micromol/L and 566.3 micromol/L respectively, compared to their baseline in the randomized discontinuation trial of 596.8 micromol/L and 410.9 micromol/L. The corresponding 20 mg and 40 mg placebo treated groups mean blood Phe levels increased to 1509.0 micromol/L and 1164 micromol/L compared to their RDT baselines of 563.9 micromol/L and 508.2 micromol/L respectively.The 8-week PRISM-2 double-blind, placebo-controlled, randomized drug discontinuation trial consisted of 86 patients, who were randomized to either remain on Palynziq or receive matching placebo. The CHMP also considered data from an ongoing open-label extension study at 36 months, where patients being treated with Palynziq showed durability and an increase in participants reaching blood Phe thresholds of physiologically normal, as well as thresholds recommended in the U.S. and the European Union. At 36 months, 58% of the participants reached Phe levels of less than or equal to120 micromol/L, 66% reached Phe levels of less than or equal to360 micromol/L. and 72% reached Phe levels of less than or equal to600 micromol/L. These results were observed concurrent with a median increase in protein intake from intact food of 25g over baseline after 36 months on treatment. In addition, the CHMP noted that the data collected in the Phase 3 trial and extension study was suggestive of an improvement in inattention and mood symptoms as measured by the inattention subscale of the investigator-rated Attention Deficient Hyperactivity Disorder Rating Scale and the Profile of Mood States tool that was modified to be specific to PKU.

07:23 EDT Tribune Media reports Q4 adjusted EBITDA up 38% to $233.3M

07:21 EDT Tribune Media CEO expects core advertising to remain solid in Q1 - "2018 was an outstanding year for Tribune Media," said CEO Peter Kern. "We reported record consolidated revenue and Adjusted EBITDA for both the fourth quarter and full year 2018, powered by exceptionally strong political advertising revenues, significant growth in retransmission and carriage fee revenues, and a meaningful contribution to our operating results from our cable network, WGN America. Despite substantial political displacement, core advertising remained solid, delivering positive year-over-year growth from Election Day to the end of the year - a trend we expect to continue in the first quarter of 2019. In addition, our focus on containing costs across the company drove 2018 consolidated expenses down despite higher network affiliation fees Tribune Media also made progress on several strategic fronts in 2018. We continued maximizing the monetization of our real estate portfolio, reached long-term agreements with several cable and satellite providers, and, most importantly, announced our agreement to be acquired by Nexstar Media Group at a price that creates significant value for our shareholders. We continue working closely with Nexstar to gain regulatory approval of the transaction and look forward to its anticipated closing later this year."

07:13 EDT Caesars enters agreement with Carl Icahn, appoints three to board - Caesars Entertainment Corporation announced that it has entered into an agreement with Carl C. Icahn and affiliated entities regarding, among other things, the membership and composition of the Company's Board of Directors. Under the terms of the agreement, Keith Cozza, Courtney Mather and James Nelson are being appointed to Caesars' Board of Directors, effective immediately. These appointments are subject to customary regulatory approval. In connection with the director appointments, three existing directors will step down from the Board, effective immediately. The agreement also provides the Icahn Group the right to appoint a fourth representative to the Board if a new Chief Executive Officer who is acceptable to new directors is not named within 45 days of this agreement. Messrs. Mather and Cozza will each serve a term expiring at Caesars Entertainment's 2019 Annual Meeting of Stockholders. and will be nominated by the Company on its slate of nominees for election as directors at the 2019 Annual Meeting. Mr. Nelson will serve in the class of directors who will be elected at the 2020 Annual Stockholders Meeting. Pursuant to the agreement, the Icahn Group (IEP), which beneficially owns 9.78% of Caesars' outstanding shares, has agreed to vote all of its shares in favor of each of Caesars' Board nominees at the Company's 2019 Annual Meeting, which has not yet been scheduled and thereafter while its designees are board members. The Icahn Group will also be subject to certain customary standstill provisions. Mr. Cozza will join the Governance and Corporate Responsibility Committee, Mr. Mather will be appointed to the Company's Compensation and Management Development Committee, and Mr. Nelson will be appointed to the Company's Audit Committee. Additionally, Messrs. Cozza and Mather will be appointed to the Strategy and Finance Committee and the Ad Hoc CEO Search Committee. In connection with the 2019 Annual Meeting, the Board will propose further enhancements to its governance processes, asking that stockholders approve amendments to its Certificate of Incorporation to permit stockholders owning at least 15% of the Company's outstanding shares to call a special meeting of stockholders and prohibit the adoption of a stockholder rights plan with a triggering threshold below 20% of the then outstanding shares, except in limited circumstances.

07:07 EDT Caesars enters agreement with Carl Icahn, adds three to board - Caesars Entertainment Corporation announced that it has entered into an agreement with Carl C. Icahn and affiliated entities regarding, among other things, the membership and composition of the Company's Board of Directors. Under the terms of the agreement, Keith Cozza, Courtney Mather and James Nelson are being appointed to Caesars' Board of Directors, effective immediately. These appointments are subject to customary regulatory approval. In connection with the director appointments, three existing directors will step down from the Board, effective immediately. The agreement also provides the Icahn Group the right to appoint a fourth representative to the Board if a new Chief Executive Officer who is acceptable to new directors is not named within 45 days of this agreement. Messrs. Mather and Cozza will each serve a term expiring at Caesars Entertainment's 2019 Annual Meeting of Stockholders. and will be nominated by the Company on its slate of nominees for election as directors at the 2019 Annual Meeting. Mr. Nelson will serve in the class of directors who will be elected at the 2020 Annual Stockholders Meeting. Pursuant to the agreement, the Icahn Group (IEP), which beneficially owns 9.78% of Caesars' outstanding shares, has agreed to vote all of its shares in favor of each of Caesars' Board nominees at the Company's 2019 Annual Meeting, which has not yet been scheduled and thereafter while its designees are board members. The Icahn Group will also be subject to certain customary standstill provisions. Mr. Cozza will join the Governance and Corporate Responsibility Committee, Mr. Mather will be appointed to the Company's Compensation and Management Development Committee, and Mr. Nelson will be appointed to the Company's Audit Committee. Additionally, Messrs. Cozza and Mather will be appointed to the Strategy and Finance Committee and the Ad Hoc CEO Search Committee. In connection with the 2019 Annual Meeting, the Board will propose further enhancements to its governance processes, asking that stockholders approve amendments to its Certificate of Incorporation to permit stockholders owning at least 15% of the Company's outstanding shares to call a special meeting of stockholders and prohibit the adoption of a stockholder rights plan with a triggering threshold below 20% of the then outstanding shares, except in limited circumstances.

07:03 EDT Novo Nordisk files for label update for Fiasp to EMA and FDA for child use - Novo Nordisk announced that it has submitted label updates to the European Medicines Agency and the U.S. Food and Drug Administration for Fiasp, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. The submissions are based on the results from the onset 7 trial which investigated the efficacy and safety of Fiasp compared with conventional insulin aspart in children and adolescents with type 1 diabetes. The company anticipates a response from the EMA later this year, and from the FDA in early 2020.

07:02 EDT C.H. Robinson acquires The Space Cargo Group for about $48M in cash - C.H. Robinson continues to expand its global network with its announcement of the acquisition of The Space Cargo Group on February 28, 2019. Space Cargo is a leading provider of international freight forwarding, customs brokerage, and other logistics services in Spain and Colombia. C.H. Robinson purchased The Space Cargo Group for approximately approximately $48M in cash. The acquisition is expected to be accretive in 2019 and will be financed through existing cash.

06:58 EDT Foot Locker CEO says fundamentals of core business are strong - "The fundamentals of our core business remain strong and led to meaningful improvement in our financial results, not only during the fourth quarter but throughout 2018," said Richard Johnson, chairman and CEO. "This positive performance was made possible by our team's unrelenting focus on providing compelling assortments to our customers, launching exciting collaborations with our strategic partners, both long-standing and new, and making our stores and digital channels unique and exciting destinations."

06:55 EDT Sonoco appoints Julie Albrecht as CFO - Sonoco announced that Julie Albrecht has assumed responsibilities as the company's Vice President and CFO, effective today. Albrecht was named the company's CFO-elect in December 2018, and is replacing Barry Saunders, Senior Vice President and most recent CFO, who is retiring on April 1.

06:37 EDT ImmunoGen announces Phase 3 FORWARD I trial did not meet PFS primary endpoint - ImmunoGen announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha, or FRa-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival, or PFS, in either the entire study population or in the pre-specified subset of patients with high FRa expression. The FORWARD I Phase 3 trial randomized 366 patients 2:1 to receive either mirvetuximab soravtansine or the physician's choice of single-agent chemotherapy. Eligibility criteria included patients with platinum-resistant ovarian cancer that expressed medium or high levels of FRa who have been treated with up to three prior regimens. The primary endpoint of this study was PFS, which was assessed using the Hochberg procedure in the entire study population and in the subset of patients with high FRa expression. The Hochberg procedure enables the simultaneous testing of two overlapping populations. Under this statistical analysis plan, if the p-value of the primary endpoint in either population is greater than 0.05, the p-value in the other population needs to be less than or equal to 0.025 to achieve statistical significance. In the entire study population, the confirmed overall response rate was higher for mirvetuximab soravtansine than for chemotherapy, without a significant difference in the primary endpoint of PFS or overall survival. In the pre-specified high FRa subgroup PFS was longer in patients who received mirvetuximab soravtansine compared with chemotherapy. Given that the p-value in the entire study population exceeded 0.05, the statistical analysis plan for the study required the p-value in the high subset to be less than or equal to 0.025 to achieve statistical significance. Confirmed overall response rate was higher for mirvetuximab soravtansine than for chemotherapy. Overall survival was longer in patients who received mirvetuximab soravtansine compared with chemotherapy. Mirvetuximab soravtansine was well-tolerated, with fewer patients experiencing grade 3 or greater adverse events, fewer dose reductions and fewer discontinuations due to drug-related adverse events compared with chemotherapy. The safety profile of mirvetuximab soravtansine was confirmed, with the most common adverse events including nausea, diarrhea and blurred vision.

06:18 EDT Innovus Pharmaceuticals gets Health Canada approval to market Diabasens as NHP - Innovus Pharmaceuticals announced that it received approval from Health Canada to market its product Diabasens as a natural health product, or NHP, for the indication to relieve cutaneous pain associated with diabetic neuropathy. The product will be available as an over-the-counter or behind the counter product and will not require a prescription.

06:07 EDT Pattern Energy appoints Esben Pedersen CFO - Effective April 1, the following changes will be made to the executive roles of three team members in order to better position the business to meet the opportunities and growth targets ahead. Mike Garland retains the role of CEO and, as such, is responsible for overall business strategy, growth plan and accountability to the board. Mike Lyon will be taking over the responsibilities of president from Mike Garland. Lyon will be responsible for the overall operations of Pattern Energy and the execution of its business plan. Esben Pedersen will be appointed to the role of CFO of Pattern Energy and will be responsible for capital strategy, financial planning, reporting and financial operations for the business. Pedersen also serves as CFO of Pattern Development.

06:04 EDT Shell says Dutch prosecutors plan charges over Nigerian oil deal - Shell says in a statement that "We have been informed by the Dutch Public Prosecutor's Office that they are nearing the conclusion of their investigation and are preparing to prosecute Royal Dutch Shell plc for criminal charges directly or indirectly related to the 2011 settlement of disputes over Oil Prospecting License 245 in Nigeria. As appropriate, we will provide updates as this matter progresses."

05:29 EDT CBS announces strategic relationship with Canvs - CBS announced a strategic relationship with Canvs. CBS will integrate Canvs Surveys, the only AI-powered topical and emotional analysis platform to automate the coding of open-ended responses to survey questions. The partnership represents a paradigm shift in how research about shows, characters, plot lines and other topics is performed. CBS Television City Research Center, the company's world-class consumer research and analytics facility in Las Vegas, currently conducts over 6,000 individual surveys during pilot-testing alone. The integration enables CBS to replace the traditionally time-consuming hand-coding of survey responses with the lightning speed of automation, a move that increases the number of insights that can be obtained and opens up the ability to contextualize survey responses in an unprecedented fashion.

05:12 EDT Algonquin Power establishes at-the-market equity program - Algonquin Power announced that it has established an at-the-market equity program, or ATM Program, that allows APUC to issue up to $250M of common shares from treasury to the public from time to time, at APUC's discretion, at the prevailing market price when issued on the Toronto Stock Exchange, the New York Stock Exchange or on any other existing trading market for the Common Shares in Canada or the United States. The ATM Program provides APUC with additional financing flexibility should it be required in the future. The volume and timing of distributions under the ATM Program, if any, will be determined at APUC's sole discretion. The ATM Program will be effective until October 19, 2020 unless terminated prior to such date by APUC or otherwise in accordance with the terms of the equity distribution agreement dated February 28, 2019. APUC intends to use the net proceeds from the ATM Program, if any, to fund acquisitions, general and administrative expenses, working capital needs, repayment of indebtedness and/or other general corporate purposes. Sales of the Common Shares through the ATM Program will be made pursuant to the terms of the Equity Distribution Agreement among APUC and RBC Dominion Securities Inc., J.P. Morgan Securities Canada Inc., Merrill Lynch Canada Inc., Scotia Capital Inc. and TD Securities, and RBC Capital Markets, , J.P. Morgan Securities LLC, Merrill Lynch, Pierce Fenner & Smith Incorporated, Scotia Capital, and TD Securities.